Literature DB >> 23392369

Pretreatment with midazolam blunts the rise in intracranial pressure associated with ketamine sedation for lumbar puncture in children.

Kathryn Michalczyk1, Janice E Sullivan, John W Berkenbosch.   

Abstract

OBJECTIVE: Ketamine has a long history of use during pediatric procedural sedation. Concerns about raising intracranial pressure may limit use in certain situations. Whereas some data suggest that benzodiazepine coadministration may blunt this response, pediatric data during procedural sedation do not exist. We evaluated the effects of midazolam pretreatment on intracranial pressure during ketamine sedation in children.
DESIGN: Prospective, randomized clinical study.
SETTING: Outpatient Medical Observation unit at Kosair Children's Hospital. PATIENTS: A total of 25 oncology patients in whom sedated lumbar puncture was scheduled.
INTERVENTIONS: Patients alternated between sedation in Group A (midazolam/ketamine prior to lumbar puncture) or Group B (ketamine only prior to lumbar puncture). Opening pressure, medication doses, sedation depth, and complications were recorded. A control group of non-ketamine-sedated patients (Group C) was added to differentiate drug vs. disease-specific opening pressure changes. Between-group differences were compared by linear mixed effects model or contingency table with p < 0.05 considered significant.
MEASUREMENTS AND MAIN RESULTS: Twenty-five patients aged 82 ± 49 months were sedated 84 times. Thirty-five sedations were in Group A, 39 in Group B, and 10 in Group C. Mean (95% confidence interval) adjusted opening pressure in Group A (22.0 [12.3, 22.2] cm H2O) was lower than Group B (26.5 [24.0, 29.2] cm H2O, p = 0.013). Opening pressure in Group C (17.3 [12.3, 22.2] cm H2O) was lower than in Group B (p = 0.002) but not in Group A (p = 0.096). Ketamine doses were similar between Groups A and B (1.4 ± 0.6 mg/kg vs. 1.4 ± 0.4 mg/kg, p = NS). Mean midazolam pretreatment dose was 0.09 ± 0.02 mg/kg and did not correlate with measured opening pressure. Four patients, all in Group B, experienced significant emergence reactions.
CONCLUSION: While pretreatment with midazolam is associated with a reduction in intracranial pressure compared with sedation with ketamine alone, ketamine-containing regimens are associated with higher opening pressures than non-ketamine-containing regimens.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23392369     DOI: 10.1097/PCC.0b013e3182720459

Source DB:  PubMed          Journal:  Pediatr Crit Care Med        ISSN: 1529-7535            Impact factor:   3.624


  6 in total

1.  Ketamine does not increase intracranial pressure compared with opioids: meta-analysis of randomized controlled trials.

Authors:  Xin Wang; Xibing Ding; Yao Tong; Jiaying Zong; Xiang Zhao; Hao Ren; Quan Li
Journal:  J Anesth       Date:  2014-05-24       Impact factor: 2.078

2.  Pre-emptive small dose of fentanyl suppresses fentanyl-induced cough: a meta-analysis of randomized controlled trials.

Authors:  Bo-Xiang Du; Liang Cao; Wei-Liang Zhao; Zhi-Hua Xu; Jie Song; Xue-Yin Shi
Journal:  Int J Clin Exp Med       Date:  2014-04-15

Review 3.  Reference range of cerebrospinal fluid opening pressure in children: historical overview and current data.

Authors:  Robert A Avery
Journal:  Neuropediatrics       Date:  2014-05-27       Impact factor: 1.947

Review 4.  Interpretation of lumbar puncture opening pressure measurements in children.

Authors:  Robert A Avery
Journal:  J Neuroophthalmol       Date:  2014-09       Impact factor: 3.042

5.  The injection rate of intravenous midazolam significantly influences the occurrence of paradoxical reaction in pediatric patients.

Authors:  Abbas Moallemy; Saeed Hoseini Teshnizi; Masood Mohseni
Journal:  J Res Med Sci       Date:  2014-10       Impact factor: 1.852

Review 6.  Role of ketamine in acute postoperative pain management: a narrative review.

Authors:  Brian M Radvansky; Khushbu Shah; Anant Parikh; Anthony N Sifonios; Vanny Le; Jean D Eloy
Journal:  Biomed Res Int       Date:  2015-10-01       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.